Atlas Antibodies manufactures a wide selection of PrecisA Monoclonals and Triple A Polyclonals targeting: Cancer Stem Cell , Mechanisms in Cancer, Glioma, Neuroendocrine Neoplasms, Oncology Biomarkers, Epithelial-to-Mesenchymal Transition, GPCRs, Colorectal, Breast Cancer and more. The antibodies are validated in IHC, WB and ICC-IF. Enhanced validation is applied as an extra layer of antibodies validation thus ensuring high specificity and selectivity for the target proteins.
Cancer Catalog: antibodies for 17 cancer types
Triple A Polyclonals antibodies targeting the top 20 genes associated with unfavorable and favourable prognosis
